Pfiz­er bags an FDA OK for PARP play­er ta­la­zoparib — now the hard part be­gins

Pfiz­er has picked up an ap­proval for ta­la­zoparib, its PARP in­hibitor for a ge­net­i­cal­ly de­fined line of breast can­cer. And now the phar­ma play­er can jump in­to a crowd­ed mar­ket where As­traZeneca’s ri­val Lyn­parza is way out in front of the pack.

The Pfiz­er drug, which is hit­ting the mar­ket as Talzen­na, fig­ured promi­nent­ly in Pfiz­er’s $14 bil­lion Medi­va­tion buy­out. The then Medi­va­tion CEO David Hung pitched ta­la­zoparib as a block­buster-to-be as Sanofi stepped up first with an of­fer. Now Pfiz­er gets to find out just how much it can make as the fourth en­try in the field, be­hind Clo­vis and Tesaro as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER